Compare ADAG & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAG | EDAP |
|---|---|---|
| Founded | 2011 | 1979 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 163.4M |
| IPO Year | 2020 | 1998 |
| Metric | ADAG | EDAP |
|---|---|---|
| Price | $3.78 | $3.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 222.3K | 44.2K |
| Earning Date | 03-24-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,688.61 | N/A |
| Revenue Next Year | $17.39 | $7.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.21 |
| 52 Week High | $4.58 | $5.05 |
| Indicator | ADAG | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 44.61 |
| Support Level | $1.69 | $3.51 |
| Resistance Level | $4.58 | $4.32 |
| Average True Range (ATR) | 0.47 | 0.33 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 44.97 | 49.04 |
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.